doi: 10.2165/11534750-000000000-00000 49 HanY
Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): A phase 3, double-blind, randomised, multicentre, placebo-controlled trial
A 2023 analysis found that creatine supplementation with resistance training may reduce body fat in people ages 50 years or older
Many NexLife members report noticing reduced appetite within the first 12 weeks
You may feel a mild soreness at the injection site for a few hours
Conversely, compared with the HFD group, after tirzepatide treatment, we identified 526 significant metabolites (377 upregulated, 149 downregulated), as shown in the heat map (Supplementary Fig